14800-DvRappard

65 Intrathecal baclofen treatment: metachromatic leukodystrophy versus spastic cerebral palsy 4 Table 1 . Patient characteristics Patient characteristics SMLD DMLD SCP Sex (n) Male Female 4 4 2 4 4 Clinical subtype (n) Late infantile Early juvenile Late juvenile Adult 0 3 5 0 0 0 2 0 Type of predominant movement disorder (n) Spastic Dyskinetic 8 0 0 2 8 0 Age at diagnosis Mean (range) 8y 0m (5y – 14y) 8y 0m (7y – 9y) Age when wheelchair dependent Mean (range) 9y 0m (6y – 17y) 8y 6m (8y – 9y) Age at pump implantation Mean (range) 11y 0m (6y – 24y) 9y 6m (9y – 10y) 11y 0m (5y – 26y) GMFC-MLD /GMFCS level* (n) 3 4 5 6 1 2 4 1 0 0 2 0 0 3 5 Cathetertip (n) C4 Th4 Th10 0 5 3 2 0 0 0 3 5 Purpose of ITB (multiple goals possible) (n) Improve care Decrease pain Improve transfers Improve sitting position Prevent contractures 7 1 1 3 0 0 2 0 1 0 8 2 0 1 1 Complications (n) Pump infection ** Catheter disconnection *** 0 1 0 0 1 1 CSF = cerebral spinal fluid; GMFC-MLD = gross motor function classification in metachromatic leukodystrophy; ITB = intrathecal baclofen; MLD = metachromatic leukodystrophy; SCP = spastic cerebral palsy. * Score at pump implantation ** at 0.5 month: negative cultures, removal of the pump. Second implantation included in the study *** One SMLD patient at 0.5 month: revision of the catheter; One SCP patient at 1 month: revision of the catheter.